<DOC>
	<DOCNO>NCT02081872</DOCNO>
	<brief_summary>UPGRADE aim see whether data Pharmacogenomic Testing ( PGx ) help physician manage patient medication regimens assess test effect reduce adverse drug reaction , hospitalization emergency department visit . The way individual process drug part determine gene , know genetic variation human way drug metabolize . The study way gene affect person 's response drug know `` Pharmacogenomics . ''</brief_summary>
	<brief_title>Utility PharmacoGenomics Reducing Adverse Drug Effects</brief_title>
	<detailed_description />
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<criteria>Subject plan undergo current index PGx test time enrollment underwent current index PGx test within prior 1year period , gene know influence metabolism least one target drug Subject age â‰¥18 year Subject able willing provide write informed consent Subject reveals history least one TDAE inadequate therapeutic effect target drug 12month period precede expect receipt PGx test result Subject take investigational medication interventional trial would interfere participation registry Subject currently hospitalize Subject 's medical medication history unavailable 90day period precede follow receipt pharmacogenomic test result Subject unable provide accurate history due mental incapacity Subject know undergone prior pharmacogenomic testing ( exclusive current index PGx test ) gene specific target drug within 2year period precede enrollment result previously evaluate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pharmacogenomics</keyword>
	<keyword>Target Drug Related Adverse Events ( TDAE )</keyword>
</DOC>